Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q99661
UPID:
KIF2C_HUMAN
Alternative names:
Kinesin-like protein 6; Mitotic centromere-associated kinesin
Alternative UPACC:
Q99661; B3ITR9; Q5JR88; Q6ICU1; Q96C18; Q96HB8; Q9BWV8
Background:
Kinesin-like protein KIF2C, also known as Mitotic centromere-associated kinesin, plays a pivotal role in mitotic cell microtubule depolymerization, as evidenced by its complex formation with KIF18B. It is instrumental in chromosome segregation, facilitating chromosome congression and the lateral to end-on conversion of chromosome-microtubule attachment.
Therapeutic significance:
Understanding the role of Kinesin-like protein KIF2C could open doors to potential therapeutic strategies.